nodes	percent_of_prediction	percent_of_DWPC	metapath
Procainamide—Lucanthone—TOP1—systemic scleroderma	0.0299	0.798	CrCbGaD
Procainamide—Sunitinib—BLK—systemic scleroderma	0.00758	0.202	CrCbGaD
Procainamide—DNMT1—Budesonide—Mometasone—systemic scleroderma	0.00501	0.291	CbGdCrCtD
Procainamide—SCN11A—digestive system—systemic scleroderma	0.00481	0.0665	CbGeAlD
Procainamide—DNMT1—connective tissue—systemic scleroderma	0.00435	0.0601	CbGeAlD
Procainamide—DNMT1—skin of body—systemic scleroderma	0.00393	0.0543	CbGeAlD
Procainamide—SCN7A—lung—systemic scleroderma	0.00341	0.0472	CbGeAlD
Procainamide—DNMT1—digestive system—systemic scleroderma	0.00314	0.0434	CbGeAlD
Procainamide—DNMT1—Betamethasone—Mometasone—systemic scleroderma	0.00306	0.178	CbGdCrCtD
Procainamide—DNMT1—Dexamethasone—Mometasone—systemic scleroderma	0.00306	0.178	CbGdCrCtD
Procainamide—SCN9A—tendon—systemic scleroderma	0.00305	0.0421	CbGeAlD
Procainamide—DNMT1—tendon—systemic scleroderma	0.00299	0.0413	CbGeAlD
Procainamide—DNMT1—Budesonide—Prednisone—systemic scleroderma	0.00273	0.159	CbGdCrCtD
Procainamide—SCN4A—tendon—systemic scleroderma	0.00272	0.0376	CbGeAlD
Procainamide—SCN9A—lung—systemic scleroderma	0.00267	0.037	CbGeAlD
Procainamide—DNMT1—lung—systemic scleroderma	0.00262	0.0363	CbGeAlD
Procainamide—SLC22A2—digestive system—systemic scleroderma	0.00262	0.0363	CbGeAlD
Procainamide—Chills—Azathioprine—systemic scleroderma	0.00251	0.00287	CcSEcCtD
Procainamide—Hallucination—Mycophenolic acid—systemic scleroderma	0.0025	0.00287	CcSEcCtD
Procainamide—Renal failure—Lisinopril—systemic scleroderma	0.00248	0.00284	CcSEcCtD
Procainamide—Feeling abnormal—Pentoxifylline—systemic scleroderma	0.00247	0.00283	CcSEcCtD
Procainamide—Anorexia—Mometasone—systemic scleroderma	0.00247	0.00283	CcSEcCtD
Procainamide—Gastrointestinal pain—Pentoxifylline—systemic scleroderma	0.00245	0.00281	CcSEcCtD
Procainamide—SLC22A3—connective tissue—systemic scleroderma	0.00245	0.0339	CbGeAlD
Procainamide—Cardiac disorder—Leflunomide—systemic scleroderma	0.00245	0.00281	CcSEcCtD
Procainamide—Oliguria—Methotrexate—systemic scleroderma	0.00243	0.00279	CcSEcCtD
Procainamide—ACHE—tendon—systemic scleroderma	0.00243	0.0336	CbGeAlD
Procainamide—Urticaria—Pentoxifylline—systemic scleroderma	0.00238	0.00273	CcSEcCtD
Procainamide—Myalgia—Captopril—systemic scleroderma	0.00237	0.00272	CcSEcCtD
Procainamide—Arthralgia—Captopril—systemic scleroderma	0.00237	0.00272	CcSEcCtD
Procainamide—Abdominal pain—Pentoxifylline—systemic scleroderma	0.00237	0.00272	CcSEcCtD
Procainamide—Body temperature increased—Pentoxifylline—systemic scleroderma	0.00237	0.00272	CcSEcCtD
Procainamide—Hepatic enzyme increased—Methotrexate—systemic scleroderma	0.00237	0.00271	CcSEcCtD
Procainamide—Chills—Leflunomide—systemic scleroderma	0.00237	0.00271	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Mometasone—systemic scleroderma	0.00236	0.0027	CcSEcCtD
Procainamide—Agranulocytosis—Lisinopril—systemic scleroderma	0.00236	0.0027	CcSEcCtD
Procainamide—Discomfort—Captopril—systemic scleroderma	0.00234	0.00269	CcSEcCtD
Procainamide—Cardiac disorder—Mycophenolic acid—systemic scleroderma	0.00234	0.00268	CcSEcCtD
Procainamide—Neutropenia—Mycophenolate mofetil—systemic scleroderma	0.00232	0.00266	CcSEcCtD
Procainamide—Bradycardia—Lisinopril—systemic scleroderma	0.00231	0.00264	CcSEcCtD
Procainamide—SCN1A—lung—systemic scleroderma	0.0023	0.0318	CbGeAlD
Procainamide—Vasculitis—Methotrexate—systemic scleroderma	0.0023	0.00263	CcSEcCtD
Procainamide—Confusional state—Captopril—systemic scleroderma	0.00229	0.00263	CcSEcCtD
Procainamide—Chills—Mycophenolic acid—systemic scleroderma	0.00226	0.00259	CcSEcCtD
Procainamide—Ill-defined disorder—Azathioprine—systemic scleroderma	0.00226	0.00259	CcSEcCtD
Procainamide—Hallucination—Lisinopril—systemic scleroderma	0.00226	0.00258	CcSEcCtD
Procainamide—Decreased appetite—Mometasone—systemic scleroderma	0.00225	0.00258	CcSEcCtD
Procainamide—Dysgeusia—Leflunomide—systemic scleroderma	0.00225	0.00258	CcSEcCtD
Procainamide—SLC22A3—smooth muscle tissue—systemic scleroderma	0.00224	0.031	CbGeAlD
Procainamide—Shock—Captopril—systemic scleroderma	0.00224	0.00256	CcSEcCtD
Procainamide—Thrombocytopenia—Captopril—systemic scleroderma	0.00223	0.00255	CcSEcCtD
Procainamide—SCN5A—digestive system—systemic scleroderma	0.00222	0.0306	CbGeAlD
Procainamide—Hypersensitivity—Pentoxifylline—systemic scleroderma	0.00221	0.00253	CcSEcCtD
Procainamide—Depression—Mycophenolate mofetil—systemic scleroderma	0.00221	0.00253	CcSEcCtD
Procainamide—Malaise—Azathioprine—systemic scleroderma	0.00219	0.00251	CcSEcCtD
Procainamide—Renal failure—Mycophenolate mofetil—systemic scleroderma	0.00218	0.00249	CcSEcCtD
Procainamide—Anorexia—Captopril—systemic scleroderma	0.00217	0.00248	CcSEcCtD
Procainamide—Asthenia—Pentoxifylline—systemic scleroderma	0.00215	0.00247	CcSEcCtD
Procainamide—Ill-defined disorder—Leflunomide—systemic scleroderma	0.00213	0.00244	CcSEcCtD
Procainamide—Hypotension—Captopril—systemic scleroderma	0.00213	0.00243	CcSEcCtD
Procainamide—Pruritus—Pentoxifylline—systemic scleroderma	0.00212	0.00243	CcSEcCtD
Procainamide—Gastrointestinal pain—Mometasone—systemic scleroderma	0.00212	0.00243	CcSEcCtD
Procainamide—SCN3A—tendon—systemic scleroderma	0.00211	0.0292	CbGeAlD
Procainamide—Flushing—Lisinopril—systemic scleroderma	0.0021	0.00241	CcSEcCtD
Procainamide—Angioedema—Leflunomide—systemic scleroderma	0.0021	0.0024	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Captopril—systemic scleroderma	0.00207	0.00237	CcSEcCtD
Procainamide—Malaise—Leflunomide—systemic scleroderma	0.00207	0.00237	CcSEcCtD
Procainamide—Myalgia—Azathioprine—systemic scleroderma	0.00207	0.00237	CcSEcCtD
Procainamide—Arthralgia—Azathioprine—systemic scleroderma	0.00207	0.00237	CcSEcCtD
Procainamide—Agranulocytosis—Mycophenolate mofetil—systemic scleroderma	0.00207	0.00237	CcSEcCtD
Procainamide—Diarrhoea—Pentoxifylline—systemic scleroderma	0.00205	0.00235	CcSEcCtD
Procainamide—Abdominal pain—Mometasone—systemic scleroderma	0.00205	0.00235	CcSEcCtD
Procainamide—Body temperature increased—Mometasone—systemic scleroderma	0.00205	0.00235	CcSEcCtD
Procainamide—Discomfort—Azathioprine—systemic scleroderma	0.00205	0.00234	CcSEcCtD
Procainamide—SCN10A—lung—systemic scleroderma	0.00204	0.0282	CbGeAlD
Procainamide—Chills—Lisinopril—systemic scleroderma	0.00203	0.00233	CcSEcCtD
Procainamide—Ill-defined disorder—Mycophenolic acid—systemic scleroderma	0.00203	0.00233	CcSEcCtD
Procainamide—Bradycardia—Mycophenolate mofetil—systemic scleroderma	0.00202	0.00232	CcSEcCtD
Procainamide—Cardiac failure—Prednisone—systemic scleroderma	0.00199	0.00228	CcSEcCtD
Procainamide—Lethargy—Prednisone—systemic scleroderma	0.00199	0.00228	CcSEcCtD
Procainamide—Dizziness—Pentoxifylline—systemic scleroderma	0.00198	0.00227	CcSEcCtD
Procainamide—Decreased appetite—Captopril—systemic scleroderma	0.00198	0.00227	CcSEcCtD
Procainamide—Hallucination—Mycophenolate mofetil—systemic scleroderma	0.00198	0.00226	CcSEcCtD
Procainamide—Malaise—Mycophenolic acid—systemic scleroderma	0.00198	0.00226	CcSEcCtD
Procainamide—Arthralgia—Leflunomide—systemic scleroderma	0.00196	0.00224	CcSEcCtD
Procainamide—Myalgia—Leflunomide—systemic scleroderma	0.00196	0.00224	CcSEcCtD
Procainamide—SLC22A4—digestive system—systemic scleroderma	0.00195	0.0269	CbGeAlD
Procainamide—Thrombocytopenia—Azathioprine—systemic scleroderma	0.00194	0.00223	CcSEcCtD
Procainamide—Dysgeusia—Lisinopril—systemic scleroderma	0.00193	0.00221	CcSEcCtD
Procainamide—Discomfort—Leflunomide—systemic scleroderma	0.00193	0.00221	CcSEcCtD
Procainamide—Vomiting—Pentoxifylline—systemic scleroderma	0.00191	0.00219	CcSEcCtD
Procainamide—Psychotic disorder—Prednisone—systemic scleroderma	0.0019	0.00218	CcSEcCtD
Procainamide—Convulsion—Mycophenolic acid—systemic scleroderma	0.0019	0.00218	CcSEcCtD
Procainamide—Feeling abnormal—Captopril—systemic scleroderma	0.00187	0.00215	CcSEcCtD
Procainamide—Arthralgia—Mycophenolic acid—systemic scleroderma	0.00187	0.00214	CcSEcCtD
Procainamide—Myalgia—Mycophenolic acid—systemic scleroderma	0.00187	0.00214	CcSEcCtD
Procainamide—Gastrointestinal pain—Captopril—systemic scleroderma	0.00186	0.00213	CcSEcCtD
Procainamide—Asthenia—Mometasone—systemic scleroderma	0.00186	0.00213	CcSEcCtD
Procainamide—SCN3A—lung—systemic scleroderma	0.00186	0.0257	CbGeAlD
Procainamide—Hypotension—Azathioprine—systemic scleroderma	0.00186	0.00212	CcSEcCtD
Procainamide—SLC22A4—tendon—systemic scleroderma	0.00185	0.0256	CbGeAlD
Procainamide—Cardiac arrest—Prednisone—systemic scleroderma	0.00185	0.00212	CcSEcCtD
Procainamide—Cardiac disorder—Mycophenolate mofetil—systemic scleroderma	0.00184	0.00211	CcSEcCtD
Procainamide—Discomfort—Mycophenolic acid—systemic scleroderma	0.00184	0.00211	CcSEcCtD
Procainamide—Thrombocytopenia—Leflunomide—systemic scleroderma	0.00184	0.0021	CcSEcCtD
Procainamide—Pruritus—Mometasone—systemic scleroderma	0.00183	0.0021	CcSEcCtD
Procainamide—Ill-defined disorder—Lisinopril—systemic scleroderma	0.00183	0.0021	CcSEcCtD
Procainamide—Hepatic failure—Methotrexate—systemic scleroderma	0.00181	0.00207	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.00181	0.00207	CcSEcCtD
Procainamide—Angioedema—Lisinopril—systemic scleroderma	0.0018	0.00207	CcSEcCtD
Procainamide—Confusional state—Mycophenolic acid—systemic scleroderma	0.0018	0.00207	CcSEcCtD
Procainamide—Abdominal pain—Captopril—systemic scleroderma	0.0018	0.00206	CcSEcCtD
Procainamide—Body temperature increased—Captopril—systemic scleroderma	0.0018	0.00206	CcSEcCtD
Procainamide—Anorexia—Leflunomide—systemic scleroderma	0.00179	0.00205	CcSEcCtD
Procainamide—Nausea—Pentoxifylline—systemic scleroderma	0.00178	0.00204	CcSEcCtD
Procainamide—Chills—Mycophenolate mofetil—systemic scleroderma	0.00178	0.00204	CcSEcCtD
Procainamide—Malaise—Lisinopril—systemic scleroderma	0.00178	0.00204	CcSEcCtD
Procainamide—Diarrhoea—Mometasone—systemic scleroderma	0.00177	0.00203	CcSEcCtD
Procainamide—Shock—Mycophenolic acid—systemic scleroderma	0.00176	0.00202	CcSEcCtD
Procainamide—Hypotension—Leflunomide—systemic scleroderma	0.00175	0.00201	CcSEcCtD
Procainamide—Thrombocytopenia—Mycophenolic acid—systemic scleroderma	0.00175	0.00201	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.00171	0.00196	CcSEcCtD
Procainamide—Anorexia—Mycophenolic acid—systemic scleroderma	0.0017	0.00195	CcSEcCtD
Procainamide—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.00169	0.00194	CcSEcCtD
Procainamide—Arthralgia—Lisinopril—systemic scleroderma	0.00168	0.00192	CcSEcCtD
Procainamide—Myalgia—Lisinopril—systemic scleroderma	0.00168	0.00192	CcSEcCtD
Procainamide—Hypotension—Mycophenolic acid—systemic scleroderma	0.00167	0.00191	CcSEcCtD
Procainamide—DNMT1—Betamethasone—Prednisone—systemic scleroderma	0.00167	0.0971	CbGdCrCtD
Procainamide—DNMT1—Dexamethasone—Prednisone—systemic scleroderma	0.00167	0.0971	CbGdCrCtD
Procainamide—Discomfort—Lisinopril—systemic scleroderma	0.00166	0.0019	CcSEcCtD
Procainamide—Lethargy—Methotrexate—systemic scleroderma	0.00166	0.0019	CcSEcCtD
Procainamide—Vomiting—Mometasone—systemic scleroderma	0.00165	0.00189	CcSEcCtD
Procainamide—Feeling abnormal—Azathioprine—systemic scleroderma	0.00164	0.00187	CcSEcCtD
Procainamide—Asthenia—Captopril—systemic scleroderma	0.00163	0.00187	CcSEcCtD
Procainamide—Decreased appetite—Leflunomide—systemic scleroderma	0.00163	0.00187	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.00163	0.00187	CcSEcCtD
Procainamide—SLC22A4—lung—systemic scleroderma	0.00163	0.0225	CbGeAlD
Procainamide—Confusional state—Lisinopril—systemic scleroderma	0.00162	0.00186	CcSEcCtD
Procainamide—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.00162	0.00186	CcSEcCtD
Procainamide—SLC22A5—skin of body—systemic scleroderma	0.00161	0.0223	CbGeAlD
Procainamide—Pruritus—Captopril—systemic scleroderma	0.00161	0.00184	CcSEcCtD
Procainamide—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.0016	0.00184	CcSEcCtD
Procainamide—BCHE—smooth muscle tissue—systemic scleroderma	0.00159	0.022	CbGeAlD
Procainamide—Shock—Lisinopril—systemic scleroderma	0.00159	0.00182	CcSEcCtD
Procainamide—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.00158	0.00181	CcSEcCtD
Procainamide—Thrombocytopenia—Lisinopril—systemic scleroderma	0.00158	0.00181	CcSEcCtD
Procainamide—Neutropenia—Prednisone—systemic scleroderma	0.00157	0.0018	CcSEcCtD
Procainamide—Body temperature increased—Azathioprine—systemic scleroderma	0.00157	0.0018	CcSEcCtD
Procainamide—Abdominal pain—Azathioprine—systemic scleroderma	0.00157	0.0018	CcSEcCtD
Procainamide—BCHE—skin of body—systemic scleroderma	0.00157	0.0217	CbGeAlD
Procainamide—Malaise—Mycophenolate mofetil—systemic scleroderma	0.00156	0.00179	CcSEcCtD
Procainamide—Diarrhoea—Captopril—systemic scleroderma	0.00156	0.00178	CcSEcCtD
Procainamide—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.00155	0.00178	CcSEcCtD
Procainamide—Feeling abnormal—Leflunomide—systemic scleroderma	0.00155	0.00177	CcSEcCtD
Procainamide—Nausea—Mometasone—systemic scleroderma	0.00154	0.00176	CcSEcCtD
Procainamide—Anorexia—Lisinopril—systemic scleroderma	0.00154	0.00176	CcSEcCtD
Procainamide—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.00153	0.00176	CcSEcCtD
Procainamide—Hypotension—Lisinopril—systemic scleroderma	0.00151	0.00172	CcSEcCtD
Procainamide—Dizziness—Captopril—systemic scleroderma	0.0015	0.00172	CcSEcCtD
Procainamide—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.0015	0.00172	CcSEcCtD
Procainamide—Depression—Prednisone—systemic scleroderma	0.0015	0.00171	CcSEcCtD
Procainamide—Urticaria—Leflunomide—systemic scleroderma	0.00149	0.00171	CcSEcCtD
Procainamide—Abdominal pain—Leflunomide—systemic scleroderma	0.00148	0.0017	CcSEcCtD
Procainamide—Body temperature increased—Leflunomide—systemic scleroderma	0.00148	0.0017	CcSEcCtD
Procainamide—SLC22A3—lung—systemic scleroderma	0.00148	0.0204	CbGeAlD
Procainamide—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.00147	0.00169	CcSEcCtD
Procainamide—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.00147	0.00169	CcSEcCtD
Procainamide—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.00147	0.00169	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.00147	0.00168	CcSEcCtD
Procainamide—Hypersensitivity—Azathioprine—systemic scleroderma	0.00146	0.00168	CcSEcCtD
Procainamide—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.00146	0.00168	CcSEcCtD
Procainamide—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.00145	0.00167	CcSEcCtD
Procainamide—Vomiting—Captopril—systemic scleroderma	0.00145	0.00166	CcSEcCtD
Procainamide—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.00142	0.00163	CcSEcCtD
Procainamide—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.00141	0.00162	CcSEcCtD
Procainamide—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.00141	0.00162	CcSEcCtD
Procainamide—Decreased appetite—Lisinopril—systemic scleroderma	0.0014	0.0016	CcSEcCtD
Procainamide—Eosinophilia—Methotrexate—systemic scleroderma	0.00139	0.00159	CcSEcCtD
Procainamide—Shock—Mycophenolate mofetil—systemic scleroderma	0.00139	0.00159	CcSEcCtD
Procainamide—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.00138	0.00158	CcSEcCtD
Procainamide—Hypersensitivity—Leflunomide—systemic scleroderma	0.00138	0.00158	CcSEcCtD
Procainamide—Bradycardia—Prednisone—systemic scleroderma	0.00137	0.00157	CcSEcCtD
Procainamide—Diarrhoea—Azathioprine—systemic scleroderma	0.00136	0.00156	CcSEcCtD
Procainamide—Nausea—Captopril—systemic scleroderma	0.00135	0.00155	CcSEcCtD
Procainamide—Abdominal discomfort—Methotrexate—systemic scleroderma	0.00135	0.00154	CcSEcCtD
Procainamide—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.00135	0.00154	CcSEcCtD
Procainamide—Asthenia—Leflunomide—systemic scleroderma	0.00135	0.00154	CcSEcCtD
Procainamide—Hallucination—Prednisone—systemic scleroderma	0.00134	0.00153	CcSEcCtD
Procainamide—Feeling abnormal—Lisinopril—systemic scleroderma	0.00133	0.00152	CcSEcCtD
Procainamide—Pruritus—Leflunomide—systemic scleroderma	0.00133	0.00152	CcSEcCtD
Procainamide—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.00132	0.00151	CcSEcCtD
Procainamide—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.00132	0.00151	CcSEcCtD
Procainamide—Neutropenia—Methotrexate—systemic scleroderma	0.00131	0.00151	CcSEcCtD
Procainamide—Dizziness—Azathioprine—systemic scleroderma	0.00131	0.0015	CcSEcCtD
Procainamide—SLC22A5—digestive system—systemic scleroderma	0.00129	0.0178	CbGeAlD
Procainamide—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.00129	0.00147	CcSEcCtD
Procainamide—Asthenia—Mycophenolic acid—systemic scleroderma	0.00128	0.00147	CcSEcCtD
Procainamide—Diarrhoea—Leflunomide—systemic scleroderma	0.00128	0.00147	CcSEcCtD
Procainamide—Urticaria—Lisinopril—systemic scleroderma	0.00128	0.00147	CcSEcCtD
Procainamide—Body temperature increased—Lisinopril—systemic scleroderma	0.00127	0.00146	CcSEcCtD
Procainamide—Abdominal pain—Lisinopril—systemic scleroderma	0.00127	0.00146	CcSEcCtD
Procainamide—Pruritus—Mycophenolic acid—systemic scleroderma	0.00127	0.00145	CcSEcCtD
Procainamide—Vomiting—Azathioprine—systemic scleroderma	0.00126	0.00145	CcSEcCtD
Procainamide—BCHE—digestive system—systemic scleroderma	0.00125	0.0173	CbGeAlD
Procainamide—Depression—Methotrexate—systemic scleroderma	0.00125	0.00143	CcSEcCtD
Procainamide—Flushing—Prednisone—systemic scleroderma	0.00125	0.00143	CcSEcCtD
Procainamide—Dizziness—Leflunomide—systemic scleroderma	0.00124	0.00142	CcSEcCtD
Procainamide—Renal failure—Methotrexate—systemic scleroderma	0.00123	0.00141	CcSEcCtD
Procainamide—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.00123	0.00141	CcSEcCtD
Procainamide—SLC22A5—tendon—systemic scleroderma	0.00123	0.0169	CbGeAlD
Procainamide—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.00122	0.0014	CcSEcCtD
Procainamide—Vomiting—Leflunomide—systemic scleroderma	0.00119	0.00137	CcSEcCtD
Procainamide—Hypersensitivity—Lisinopril—systemic scleroderma	0.00119	0.00136	CcSEcCtD
Procainamide—Dizziness—Mycophenolic acid—systemic scleroderma	0.00118	0.00135	CcSEcCtD
Procainamide—Nausea—Azathioprine—systemic scleroderma	0.00118	0.00135	CcSEcCtD
Procainamide—Agranulocytosis—Methotrexate—systemic scleroderma	0.00117	0.00134	CcSEcCtD
Procainamide—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.00116	0.00133	CcSEcCtD
Procainamide—Asthenia—Lisinopril—systemic scleroderma	0.00116	0.00132	CcSEcCtD
Procainamide—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.00115	0.00132	CcSEcCtD
Procainamide—Pruritus—Lisinopril—systemic scleroderma	0.00114	0.00131	CcSEcCtD
Procainamide—Vomiting—Mycophenolic acid—systemic scleroderma	0.00114	0.0013	CcSEcCtD
Procainamide—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.00112	0.00128	CcSEcCtD
Procainamide—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.00112	0.00128	CcSEcCtD
Procainamide—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.00112	0.00128	CcSEcCtD
Procainamide—Nausea—Leflunomide—systemic scleroderma	0.00111	0.00128	CcSEcCtD
Procainamide—Diarrhoea—Lisinopril—systemic scleroderma	0.0011	0.00126	CcSEcCtD
Procainamide—Ill-defined disorder—Prednisone—systemic scleroderma	0.00109	0.00125	CcSEcCtD
Procainamide—SLC22A5—lung—systemic scleroderma	0.00108	0.0149	CbGeAlD
Procainamide—Angioedema—Prednisone—systemic scleroderma	0.00107	0.00123	CcSEcCtD
Procainamide—Dizziness—Lisinopril—systemic scleroderma	0.00107	0.00122	CcSEcCtD
Procainamide—Nausea—Mycophenolic acid—systemic scleroderma	0.00106	0.00122	CcSEcCtD
Procainamide—Malaise—Prednisone—systemic scleroderma	0.00106	0.00121	CcSEcCtD
Procainamide—BCHE—lung—systemic scleroderma	0.00105	0.0145	CbGeAlD
Procainamide—Cardiac disorder—Methotrexate—systemic scleroderma	0.00104	0.0012	CcSEcCtD
Procainamide—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.00104	0.00119	CcSEcCtD
Procainamide—Vomiting—Lisinopril—systemic scleroderma	0.00102	0.00117	CcSEcCtD
Procainamide—Convulsion—Prednisone—systemic scleroderma	0.00102	0.00116	CcSEcCtD
Procainamide—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.00101	0.00116	CcSEcCtD
Procainamide—Chills—Methotrexate—systemic scleroderma	0.00101	0.00116	CcSEcCtD
Procainamide—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000999	0.00114	CcSEcCtD
Procainamide—Arthralgia—Prednisone—systemic scleroderma	0.000998	0.00114	CcSEcCtD
Procainamide—Myalgia—Prednisone—systemic scleroderma	0.000998	0.00114	CcSEcCtD
Procainamide—Discomfort—Prednisone—systemic scleroderma	0.000986	0.00113	CcSEcCtD
Procainamide—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000966	0.00111	CcSEcCtD
Procainamide—Dysgeusia—Methotrexate—systemic scleroderma	0.000959	0.0011	CcSEcCtD
Procainamide—Nausea—Lisinopril—systemic scleroderma	0.000957	0.0011	CcSEcCtD
Procainamide—Shock—Prednisone—systemic scleroderma	0.000941	0.00108	CcSEcCtD
Procainamide—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000933	0.00107	CcSEcCtD
Procainamide—Anorexia—Prednisone—systemic scleroderma	0.000912	0.00104	CcSEcCtD
Procainamide—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000909	0.00104	CcSEcCtD
Procainamide—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000897	0.00103	CcSEcCtD
Procainamide—Malaise—Methotrexate—systemic scleroderma	0.000884	0.00101	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000872	0.000999	CcSEcCtD
Procainamide—Convulsion—Methotrexate—systemic scleroderma	0.000849	0.000972	CcSEcCtD
Procainamide—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000838	0.00096	CcSEcCtD
Procainamide—Arthralgia—Methotrexate—systemic scleroderma	0.000834	0.000955	CcSEcCtD
Procainamide—Myalgia—Methotrexate—systemic scleroderma	0.000834	0.000955	CcSEcCtD
Procainamide—Decreased appetite—Prednisone—systemic scleroderma	0.000832	0.000953	CcSEcCtD
Procainamide—CYP2D6—digestive system—systemic scleroderma	0.000831	0.0115	CbGeAlD
Procainamide—Discomfort—Methotrexate—systemic scleroderma	0.000824	0.000944	CcSEcCtD
Procainamide—Confusional state—Methotrexate—systemic scleroderma	0.000806	0.000924	CcSEcCtD
Procainamide—Feeling abnormal—Prednisone—systemic scleroderma	0.000788	0.000903	CcSEcCtD
Procainamide—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000783	0.000897	CcSEcCtD
Procainamide—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000782	0.000896	CcSEcCtD
Procainamide—Anorexia—Methotrexate—systemic scleroderma	0.000762	0.000873	CcSEcCtD
Procainamide—Urticaria—Prednisone—systemic scleroderma	0.00076	0.000871	CcSEcCtD
Procainamide—Body temperature increased—Prednisone—systemic scleroderma	0.000756	0.000866	CcSEcCtD
Procainamide—Abdominal pain—Prednisone—systemic scleroderma	0.000756	0.000866	CcSEcCtD
Procainamide—Hypotension—Methotrexate—systemic scleroderma	0.000747	0.000856	CcSEcCtD
Procainamide—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000729	0.000834	CcSEcCtD
Procainamide—Hypersensitivity—Prednisone—systemic scleroderma	0.000705	0.000807	CcSEcCtD
Procainamide—Decreased appetite—Methotrexate—systemic scleroderma	0.000695	0.000796	CcSEcCtD
Procainamide—Asthenia—Prednisone—systemic scleroderma	0.000686	0.000786	CcSEcCtD
Procainamide—Pruritus—Prednisone—systemic scleroderma	0.000677	0.000775	CcSEcCtD
Procainamide—Feeling abnormal—Methotrexate—systemic scleroderma	0.000659	0.000755	CcSEcCtD
Procainamide—Diarrhoea—Prednisone—systemic scleroderma	0.000655	0.00075	CcSEcCtD
Procainamide—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000654	0.000749	CcSEcCtD
Procainamide—Urticaria—Methotrexate—systemic scleroderma	0.000635	0.000728	CcSEcCtD
Procainamide—Dizziness—Prednisone—systemic scleroderma	0.000633	0.000725	CcSEcCtD
Procainamide—Body temperature increased—Methotrexate—systemic scleroderma	0.000632	0.000724	CcSEcCtD
Procainamide—Abdominal pain—Methotrexate—systemic scleroderma	0.000632	0.000724	CcSEcCtD
Procainamide—Vomiting—Prednisone—systemic scleroderma	0.000608	0.000697	CcSEcCtD
Procainamide—Hypersensitivity—Methotrexate—systemic scleroderma	0.000589	0.000675	CcSEcCtD
Procainamide—Asthenia—Methotrexate—systemic scleroderma	0.000574	0.000657	CcSEcCtD
Procainamide—Nausea—Prednisone—systemic scleroderma	0.000568	0.000651	CcSEcCtD
Procainamide—Pruritus—Methotrexate—systemic scleroderma	0.000566	0.000648	CcSEcCtD
Procainamide—Diarrhoea—Methotrexate—systemic scleroderma	0.000547	0.000627	CcSEcCtD
Procainamide—Dizziness—Methotrexate—systemic scleroderma	0.000529	0.000606	CcSEcCtD
Procainamide—Vomiting—Methotrexate—systemic scleroderma	0.000508	0.000582	CcSEcCtD
Procainamide—Nausea—Methotrexate—systemic scleroderma	0.000475	0.000544	CcSEcCtD
